SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Akoya Biosciences, Inc. (AKYA) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+86%).
- Analyst consensus target $2.40 (+86% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 41/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — AKYA
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.78
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.12
Book Value / Share$0.00
Revenue / Share$1.65
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$2.40 (+86%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-0.40 |
$42.24M |
$-14.75M |
-34.9% |
| 2020 |
$-0.45 |
$42.44M |
$-16.71M |
-39.4% |
| 2021 |
$-1.15 |
$54.92M |
$-42.94M |
-78.2% |
| 2022 |
$-1.87 |
$74.86M |
$-70.64M |
-94.4% |
| 2023 |
$-1.43 |
$96.63M |
$-63.32M |
-65.5% |
| 2024 |
$-1.12 |
$81.67M |
$-55.37M |
-67.8% |
